Home/Pipeline/Presbyopia-Correcting Contact Lenses

Presbyopia-Correcting Contact Lenses

Presbyopia

DevelopmentActive

Key Facts

Indication

Presbyopia

Phase

Development

Status

Active

Company

Clerio Vision

About Clerio Vision

Clerio Vision is a private, pre-revenue medical device innovator leveraging its proprietary LIRIC (Laser Induced Refractive Index Change) platform to address multiple multi-billion-dollar ophthalmic markets. The technology, born from University of Rochester research, uses femtosecond lasers to 'write' corrective optics inside materials, enabling novel, non-invasive solutions for presbyopia, myopia progression, post-cataract optimization, and refractive surgery. With $80M in R&D investment, a strong IP portfolio, and completed first-in-human trials, Clerio is positioned to disrupt traditional vision correction paradigms if it can successfully navigate clinical development, regulatory pathways, and market adoption.

View full company profile

Therapeutic Areas

Ophthalmology

Other Presbyopia Drugs

Drug	Company	Phase	Status
Presbyopia Treatment	Viatris (2)	NDA Submitted	Active
Presbyopia-Correcting ICL	STAAR Surgical	Research & Development	Active R&D
LB-01	Lento Bio	Discovery/IND-Enabling	Active
LB-02	Lento Bio	Discovery	Active
Intra-corneal Implant	MAG Optics	Pre-clinical	Active
NVK029	Vyluma	Phase 2	Active
ArtiPlus	Ophtec	Clinical Trials	Active
BRIMOCHOL™ PF	Tenpoint Therapeutics	NDA Submitted	Active
Qlosi™	Orasis Pharmaceuticals	Approved	Active
TSH‑001	TSH Biopharm	Phase 1/2	Active
DE-128A	Santen Pharmaceutical	Phase 2	Active
YP-10	Viatris	NDA Filed	Under FDA Review (PDUFA date set)